Prevalence of any pathological finding for inflammation (intratendinous or peritendinous inflammatory signal, bone marrow oedema at the painful sites)

Slides:

Advertisements

Similar presentations

Monthly improvements in family, social and leisure activities to week 96 (last observation carried forward imputation). Assessed using the arthritis-specific.

Advertisements

Monthly improvements in paid work productivity: overall axial spondyloarthritis population (employed patients only; last observation carried forward imputation). Assessed.

Summary of TB cases across indications and trial periods

Multivariable model of abatacept retention in biologic-naïve patients.

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Changes in evaluation indicators from baseline to 12 weeks per visit.

Without fat suppression techniques, fat and fluid both have a high-signal intensity on fluid-sensitive fast spin echo. This adult patient with a history.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

Endochondral bone formation in HLA-B27 transduced ATDC5 micromasses.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Sagittal short tau inversion recovery images of the lower spine of two different patients. Sagittal short tau inversion recovery images of the lower spine.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

Frequency of patients in flare at each time point over 3 months

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

Three different reconstructions after one single mDixon sequence of

Resolution of tophi after exposure to pegloticase.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

The distribution at baseline of inflammatory and structural lesions across vertebral bodies and posterior elements at each level from C2/C3 to L5/S1. The.

CAIA is attenuated in Nrdc – / – mice.

XY plots with regression lines (red) showing the relationship between average (left panel) and peak (right panel) tissue stress at all bone sites for dual-energy.

Serum levels of (A), C reactive protein (CRP), (B), erythrocyte sedimentation rate (ESR) and (C), calprotectin of cohort 1 (SPACE) with patients with early.

Foot maps showing the patterns of average tissue stress, peak tissue stress, urate deposition in gout and bone erosion in gout. Foot maps showing the patterns.

Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.

Treatments considered ‘Appropriate’ in at least one of the four subphenotypes of knee osteoarthritis.12 Quality of evidence is indicated by: bold=good;

Association between PGIC and change (Δ) in (A) Pain (VAS), (B) PGA, (C) FIQ, (D) HAQ, (E) Body Map, (F) MPQ). Association between PGIC and change (Δ) in.

Distribution of Tc99m-radiolabelled certolizumab pegol in hands, feet and SIJs 4–5 hours postinjection. Distribution of Tc99m-radiolabelled certolizumab.

Prescription rates of (A) NSAIDs, glucocorticoids and analgaesics, (B) TNF inhibitors and synthetic DMARDs and (C) combination therapy of NSAIDs with TNF.

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Hypothetical model of fatigue in a chronic immunological condition.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Imaging of patient 1. Imaging of patient 1. (A) Muscle MRI of both legs performed at the age of 5 years: coronal gadolinium-enhanced T1-weighted sequence.

Examples of MRI at presentation with clinically suspect arthralgia (CSA) (top panel) and at IA development (bottom panel), showing joints (A) from no inflammation.

Graphical display for QUADAS-2 results.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.

SRMs at 3 and 6 months for the final ultrasound inflammation score (USRA9) bilaterally and previously proposed scores (A) GSUS in the early RA cohort,

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

ACR20/50/70 response rates at week 24 (TP1 per-protocol set).

MRI, STIR sequence of sacroiliac joints (SIJs): minimal localised signal increase on both sides of the upper part of the left SIJ (arrows), which does.

The thickness of the subchondral bone plate for healthy subjects and patients with osteoarthritis (OA). The thickness of the subchondral bone plate for.

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Ultrasound examination and conventional radiography of the second proximal interphalangeal joint at baseline (2009) and follow-up (2013). Ultrasound examination.

Efficacy as first, second and third bDMARD in patients with axial spondyloarthritis. ASAS, Assessment of Spondylo Arthritis international Society; BASDAI,

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Satisfaction with control of RA

MRI in individuals with symptomatic knee osteoarthritis illustrating the structural abnormalities that discriminate symptomatic knee osteoarthritis best.

Schematic depiction of categories of inflammation in 350 small joints during progression from clinically suspect arthralgiato inflammatory arthritis. Schematic.

Classification tree with the selected characteristics.

(A) NKG2A and (B) NKG2C expression on NK cells in subjects with AS and HCs. The upper figure represents % of NK positive cells; the lower figure represents.

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Network graph illustrating the relation between the assessed structural abnormalities on different locations within the knee joint in the total NEO study.

Example of pathological MRI (T1-weighted sequence after gadolinium) of the ankle from a patient with peripheral spondyloarthritis (female, 46 years). ‘O’,

(A) Detailed comparison of the prevalence of single pathological lesions in both heel and knee in patients with SpA and non-SpA patients, as assessed by.

Nail photographs and MRI scans of a patient with psoriatic arthritis.

Forest plot showing the results of the meta-analysis on the effect of aerobic exercise on measured on VO2max in people with rheumatoid arthritis, spondyloarthritis.

Depiction of bone marrow oedema using different techniques

Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.

WOMAC (Western Ontario and McMaster Universities Arthritis Index) symptoms in the operated knee and contralateral knee over time and by treatment. WOMAC.

ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.

Relation of P-gp+CD69+CD4+ cells with outcome of intensive immunosuppressive therapy in patients with active proliferative lupus nephritis (LN). Relation.

MRI remission in the imaging set of patients from the RAPID-axSpA trial. MRI remission in the imaging set of patients from the RAPID-axSpA trial. Remission.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. (Included.

Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.

Presentation transcript:

Prevalence of any pathological finding for inflammation (intratendinous or peritendinous inflammatory signal, bone marrow oedema at the painful sites) or chronic (thickness of painful tendon, pathological finding of fibrous structure including rupture of the painful tendon, bone erosion or calcification/enthesophyte formation at the site of examination) changes in the lower limbs (heel and knee) between patients with SpA and no SpA. Prevalence of any pathological finding for inflammation (intratendinous or peritendinous inflammatory signal, bone marrow oedema at the painful sites) or chronic (thickness of painful tendon, pathological finding of fibrous structure including rupture of the painful tendon, bone erosion or calcification/enthesophyte formation at the site of examination) changes in the lower limbs (heel and knee) between patients with SpA and no SpA. The numbers given are proportions of sites being positive for inflammatory or chronic changes in PD and MRI in both heel and knee. Overall, only the difference between pSpA and non-SpA for chronic changes as assessed by PD was statistically significant. This finding was mainly based on the difference for bone erosions at the insertion of the Achilles’ tendon. PD, power Doppler; PDUS, power Doppler ultrasound; pSpA, peripheral spondyloarthritis; SpA, spondyloarthritis. Xenofon Baraliakos et al. RMD Open 2017;3:e000541 Copyright © BMJ Publishing Group & EULAR. All rights reserved.